R&D Relief Estimator 2026/27
Enter your qualifying R&D expenditure and company position. The tool shows your merged-scheme net benefit and, where you qualify, the ERIS payable credit. Speak to a specialist before filing.
Calculator
R&D Relief Estimator 2026/27
Enter your qualifying R&D expenditure and company position. The tool shows your merged-scheme net benefit and, where you qualify, the ERIS payable credit. Speak to a specialist before filing.
Total qualifying R&D costs for the period: staff, subcontractors or externally provided workers (EPW), software, consumables.
The R&D-qualifying fraction of payroll only. Must be no more than total qualifying expenditure above.
Loss-making companies with 30%+ R&D intensity may qualify for the higher ERIS payable credit.
Used for the 30% R&D-intensity test (ERIS). Must be greater than zero.
25% main rate, 19% small profits rate, and 26.5% on each extra £1 of profit inside the marginal relief band. Only affects the net value of the merged-scheme taxable credit for a profit-making company; a loss-making company's credit is netted at 19%.
Merged-scheme route: the 20% credit is above-the-line and taxable, so the net benefit is reduced by your CT rate (25%). Claim notification: a company claiming for the first time, or whose last claim was made more than 3 years before the end of its claim notification period, must notify HMRC within that period, which runs from the first day of the period of account to 6 months after its end, or the claim is invalid. From 1 April 2027 no claim notification form is due to be needed for claims made on or after that date (announced at Budget 2026, still to pass in the Finance Bill). These are estimates, not a filed claim. Speak to a specialist before filing.
Check your position with a startup tax specialist
A calculator gives you the shape of the answer. We confirm your exact figures, the reliefs you can claim, and what your business needs to file. No obligation, and we reply within 24 hours.
How this R&D relief estimator works
For accounting periods beginning on or after 1 April 2024, the merged R&D scheme gives a 20% above-the-line taxable expenditure credit on qualifying R&D spend. Because the credit is taxable, the net benefit is the gross credit reduced by your corporation tax rate: 15% effective at 25% CT, 16.2% at 19% CT, and about 14.7% inside the marginal relief band, where each extra £1 of profit between £50,000 and £250,000 is taxed at 26.5%. A loss-making company's credit is netted at 19%, because HMRC's notional tax deduction uses the small profits rate when there are no main-rate profits, so it's 16.2% too.
Loss-making companies with qualifying R&D spend of at least 30% of total expenditure keep access to the Enhanced R&D Intensive Support route (ERIS). ERIS gives an 86% additional deduction on qualifying spend, producing enhanced expenditure of 186% of the original spend, then a payable credit worth up to 14.5% of the surrenderable loss. The surrenderable loss can't be more than that enhanced amount or the company's unrelieved trading loss, so on £100,000 qualifying spend the most it produces is £26,970.
The 30% intensity test compares the company's relevant R&D expenditure with its total relevant expenditure for the period, and the spend of any connected companies counts too. Total expenditure is broadly what goes through the profit and loss account under GAAP, plus pre-trading costs. So £100,000 of R&D in £300,000 of total spend is 33.3% and passes, while £100,000 in £500,000 is 20% and doesn't.
A worked R&D tax credit calculation for a profitable company: £100,000 of qualifying spend gives a £20,000 credit. It's taxed as trading income, so it's worth £15,000 at 25% CT, £16,200 at 19%, or £14,700 inside the marginal relief band.
A worked calculation for a loss-making company: the same £100,000 of R&D in £300,000 of total spend passes the 30% test, so ERIS adds an £86,000 deduction (£186,000 in all). If the trading loss is at least £186,000, the whole amount can be surrendered and the credit is £26,970 (14.5% of £186,000). If the company chooses the merged scheme instead, or its R&D is only £100,000 of £500,000, the credit's £20,000 and the net cash is £16,200 after the 19% notional tax.
The estimator applies the 30% intensity test automatically from your inputs. Where ERIS applies, it shows the ERIS payable credit as the headline and the merged-scheme net benefit as an alternative, since a company can elect the merged route instead.
Every estimate assumes full loss surrender and doesn't apply the PAYE/NIC cap (£20,000 plus 300% of the company's PAYE and NIC liabilities for the period, unless it's exempt) or the subcontractor/externally-provided-worker restrictions. Flag these with a specialist before filing.
Frequently asked questions
The merged scheme gives a 20% above-the-line taxable credit. The net benefit after corporation tax is about 15% of qualifying spend at the 25% main rate, 16.2% at the 19% small profits rate, and about 14.7% inside the marginal relief band (a 26.5% marginal rate). A loss-making company nets 16.2%.
Enhanced R&D Intensive Support applies to loss-making SMEs whose qualifying R&D spend is at least 30% of total expenditure. It gives an 86% additional deduction and a payable credit worth up to 14.5% of the surrenderable loss.
The 20% credit is included in taxable profits (above the line), so a company with a 25% CT rate sees its net benefit reduced to 15% of qualifying spend. The credit is set against that period's CT bill first. Whatever's left has HMRC's notional tax deduction taken off and the PAYE cap applied, and can then be set against other tax the company owes or paid out.
ERIS requires that qualifying R&D expenditure makes up at least 30% of total company expenditure for the period. Enter your total expenditure in field 4 and the tool applies the test.
A company claiming for the first time, or whose last claim was made more than 3 years before the end of its claim notification period, must notify HMRC within that period. It runs from the first day of the period of account to 6 months after the period of account ends, and missing it makes the claim invalid. From 1 April 2027 no claim notification form is due to be needed for claims made on or after that date (announced at Budget 2026, still to pass in the Finance Bill).
No. The cap is £20,000 plus 300% of the company's PAYE and NIC liabilities for the period, unless the company is exempt, and it applies under both the merged scheme and ERIS. The estimator flags it where staff cost is low relative to total R&D spend, but doesn't compute the capped figure, because that needs the company's whole payroll. A specialist should check this before filing.
Want to be sure of your position?
Tell us about your startup situation and we will confirm your exact figures and the compliance steps that apply to you. No obligation.